VivoSeq
Metabolic & Endocrine

Obesity or Overweight

3

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

Obesity or Overweight is an early-stage landscape with 3 programs across 3 companies. The most active players are Roche, Zealand Pharma, Amgen. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 2Zealand Pharma logo

Zealand Pharma

1 program

Phase 2Amgen logo

Amgen

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Petrelintide

Zealand Pharma

Petrelintide-Matching Placebo

Roche

Phase 31

Maridebart Cafraglutide

Amgen

Approved
No programs

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Not yet recruiting1 · 25%

Clinical Trials

Trial Activity

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy and Safety of Petrelintide Co-Administered With RO7795068 in Adults With Obesity or Overweight
Not yet recruiting·Roche logoRoche·Phase 2·NCT07589686·486 enrolled
A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1 Receptor Agonists to Maridebart Cafraglutide in Adult Participants With Obesity or Overweight
Recruiting·Amgen logoAmgen·Phase 3·NCT07575399·300 enrolled
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes
Recruiting·Roche logoRoche·Phase 3·NCT07351045·2,000 enrolled
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes
Recruiting·Roche logoRoche·Phase 3·NCT07351058·1,600 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)